Oryzon Genomics SA
Research Oryzon Genomics SA (ORY) on Bullrun: market cap EUR 241.38M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerORY
- ExchangeMC
- CountrySpain
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 241.38M
- Financial periodQ4 2025
- Net income-EUR 1.01M
Valuation Snapshot
latest market cap is EUR 241.38M.
About Oryzon Genomics SA
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases.
Frequently asked questions
What is Oryzon Genomics SA's market cap?
Oryzon Genomics SA's market capitalization is EUR 241.38M.
What does Oryzon Genomics SA do?
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders.